Keyphrases
Integration Site
100%
Dihydroartemisinin
100%
Leukemia
100%
Melanoma
100%
Vemurafenib Resistance
100%
A375
61%
BRAF Inhibitor (BRAFi)
38%
Melanoma Cells
38%
Inhibitor Resistance
15%
A375 Cells
15%
Targeted Therapy
15%
MRNA Level
15%
Inhibitor Resistant
15%
BRAF V600E mutant
15%
Immune Checkpoint Blockade Antibodies
7%
Artemisia Annua
7%
Oncogene
7%
Antimalarial Drugs
7%
RNA-seq Analysis
7%
Artemisinin
7%
Survival Time
7%
Advanced Melanoma
7%
Serious Adverse Effects
7%
Xenograft
7%
Drug Resistance
7%
Low Toxicity
7%
Protein Level
7%
MEK Inhibitor (MEKi)
7%
Resistance Genes
7%
Mitogen-activated Protein Kinase Inhibitor
7%
Valine
7%
Small Molecules
7%
Glutamine
7%
Adjuvant Therapy
7%
Tumor Growth
7%
Clinical Outcomes
7%
V600E
7%
Melanoma Patients
7%
BRAF V600E
7%
Chinese Medicinals
7%
Overcoming Resistance
7%
Active Metabolite
7%
Induced Apoptosis
7%
BRAF-mutant Melanoma
7%
Vemurafenib
7%
Melanoma Mouse Model
7%
BRAF mutation
7%
Multi-target
7%
Vemurafenib-resistant
7%
Medicine and Dentistry
Friend Leukemia
100%
Dihydroartemisinin
100%
Vemurafenib
100%
Melanoma
100%
Melanoma Cell
38%
Targeted Therapy
15%
Messenger RNA
15%
Immune Checkpoint Blockade
7%
Artemisia annua
7%
Active Metabolite
7%
Programmed Cell Death
7%
Artemisinin
7%
MEK Inhibitor
7%
Malignant Neoplasm
7%
Antimalarial Agent
7%
Valine
7%
Drug Resistance
7%
Glutamine
7%
Upregulation
7%
Adverse Effect
7%
RNA Sequencing
7%
Survival Time
7%
Oncogene
7%
Xenograft
7%
Tumor Progression
7%
Pharmacology, Toxicology and Pharmaceutical Science
Friend Leukemia
100%
Vemurafenib
100%
Melanoma
100%
Dihydroartemisinin
100%
Messenger RNA
14%
Survival Time
7%
Valine
7%
Antimalarial Agent
7%
Glutamine
7%
Malignant Neoplasm
7%
Mouse Model
7%
Drug Resistance
7%
Active Metabolite
7%
Mitogen Activated Protein Kinase Kinase Inhibitor
7%
Artemisia annua
7%
Artemisinin
7%
Tumor Growth
7%